← back to search

Yuezong Bai

Ministry of Education of the People's Republic of China · CN
Area of research
Cancer Research · Oncology
Research interest
Research interests include Medicine, Oncology, Internal medicine, Lung cancer, Cancer, and Hepatocellular carcinoma.
h-index
citations
1,140
works
9
NIH funding
primary concept
email

Recent publications

LBA40 Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Annals of Oncology 2024cited by 9position: middledoi
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
EBioMedicine 2022cited by 55position: middledoi
Next-generation sequencing based detection of BRCA1 and BRCA2 large genomic rearrangements in Chinese cancer patients
Frontiers in Oncology 2022cited by 9position: middledoi
DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study
Translational Lung Cancer Research 2022cited by 3position: middledoi
A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer
BMC Cancer 2021cited by 79position: middledoi
Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
Annals of Translational Medicine 2021cited by 54position: middledoi
A Novel Ten-Gene Signature Predicting Prognosis in Hepatocellular Carcinoma
Frontiers in Cell and Developmental Biology 2020cited by 91position: middledoi
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
JAMA Oncology 2019cited by 495position: middledoi
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
JAMA Oncology 2019cited by 345position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mengli Huang · Shanghai Medical College of Fudan University5 papers (2019–2022)Wenzhuan Xie · Shanghai Medical College of Fudan University3 papers (2020–2021)Xiaochen Zhao · Xi'an University of Science and Technology2 papers (2019–2022)Chan Gao · McGill University Health Centre2 papers (2020–2021)Yating Zheng · Nanchang University2 papers (2021–2022)Shangli Cai · Hua Medicine (China)2 papers (2019–2021) · 2 papers (2021–2022)Jing Zhao · Fujian Medical University2 papers (2019–2021)Yuzhen Gao · Sir Run Run Shaw Hospital1 papers (2024–2024)Ning Ma · Jinzhou Medical University1 papers (2020–2020)Connor J. Kinslow · Columbia University1 papers (2022–2022)Chuang Qi · Xinjiang Medical University1 papers (2019–2019)Jiudi Zhong · Sun Yat-sen University1 papers (2021–2021) · 1 papers (2019–2019)Celimuge Bao · Shanghai Medical College of Fudan University1 papers (2022–2022)Dingchao Hua · Shanxi Medical University1 papers (2022–2022) · 1 papers (2022–2022)Haoqiang He · Sun Yat-sen University1 papers (2021–2021)Shiqing Chen · Anhui Medical University1 papers (2019–2019) · 1 papers (2024–2024)